Emerging studies suggest this peptide, a dual activator targeting both GLP-1 and glucose-dependent insulinotropic polypeptide , may provide a significant step forward for body treatment. Early clinical tests have shown considerable losses in abdominal mass , conceivably exceeding existing obesity medications . However , further evaluation is requir